Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AG Non-nucleoside reverse transcriptase inhibitors
J05AG05 Rilpivirine
D09720 Rilpivirine (JAN/USAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D09720 Rilpivirine (JAN/USAN/INN)
Drug groups [BR:br08330]
Antiviral
DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI)
DG00663 Rilpivirine
D09720 Rilpivirine
DG03107 Anti-HIV agent
DG01656 HIV reverse transcriptase inhibitor
DG00663 Rilpivirine
D09720 Rilpivirine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00663 Rilpivirine
D09720 Rilpivirine
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D09720 Rilpivirine
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HIV reverse transcriptase inhibitor
D09720 Rilpivirine (JAN/USAN/INN) <JP>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09720
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09720
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09720
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09720
Drug groups [BR:br08330]
Antiviral
DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI)
DG00663 Rilpivirine
DG03107 Anti-HIV agent
DG01656 HIV reverse transcriptase inhibitor
DG00663 Rilpivirine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00663 Rilpivirine
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HIV reverse transcriptase inhibitor
DG00663 Rilpivirine